Clinical Trials on Variola Major (Smallpox)

Total 2936 results

National Institute of Allergy and Infectious Diseases...

Completed

Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects

Variola Major (Smallpox)

United States
National Institute of Allergy and Infectious Diseases...

Completed

High Dose IMVAMUNE® in Vaccinia-Naive Individuals

Variola Major (Smallpox)

United States
Emergent BioSolutions
Centers for Disease Control and Prevention

Enrolling by invitation

VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection

Complication of Smallpox Vaccination
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses to Smallpox Vaccination

Smallpox Vaccine

United States
Emergent BioSolutions
Centers for Disease Control and Prevention

Completed

VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

Smallpox Vaccine Adverse Reaction

United States
Emergent BioSolutions

Completed

VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV

Smallpox Vaccine Adverse Reaction

Canada
Bristol-Myers Squibb

Terminated

Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors

Various Advanced Cancer

Australia, United States, Canada
Masimo Corporation

Completed

Pulse CO-Oximetry Noninvasive Monitoring and Laboratory Measurements of Subject Blood Samples

Various Comorbidities

United States
Emergent BioSolutions

Completed

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)

Smallpox

United States
SIGA Technologies
United States Department of Defense

Completed

Study to Assess the Safety and Pharmacokinetics of TPOXX® When Administered Orally for 28 Days

Smallpox

United States
SIGA Technologies
United States Department of Defense

Completed

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day

Smallpox

United States
SIGA Technologies
PPD; Biomedical Advanced Research and Development Authority

Completed

Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG

Smallpox

United States
SIGA Technologies
Biomedical Advanced Research and Development Authority

Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat (SIGA246-008)

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Terminated

Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Smallpox

United States
Seoul National University Hospital
HK inno.N Corporation

Completed

Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers

Smallpox

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

MVA Post-Event: Administration Timing and Boost Study

Smallpox

United States
DynPort Vaccine Company LLC, A GDIT Company

Completed

Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®

Smallpox

United States
McMaster University

Not yet recruiting

Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT (SMART)

Monkeypox

Nigeria
U.S. Army Medical Research and Development Command

Available

Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure

Smallpox | Monkeypox
Bavarian Nordic

Completed

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Trial of Smallpox Vaccine

Healthy

United States
Emergent BioSolutions

Completed

Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

Smallpox

United States
Emergent BioSolutions

Completed

Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Smallpox

United States
Emergent BioSolutions

Completed

Safety Surveillance Study of ACAM2000® Vaccinia Vaccine

Smallpox

United States
SIGA Technologies
PPD; Biomedical Advanced Research and Development Authority

Completed

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

Smallpox

United States
SIGA Technologies
Biomedical Advanced Research and Development Authority

Withdrawn

A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox

Smallpox

United States
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

Smallpox

Switzerland
National Institute of Allergy and Infectious Diseases...

Completed

ACAM 3000 MVA at Harvard Medical School

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Expanded Dryvax Dilution Study in Previously Vaccinated Adults

Smallpox

United States
Seoul National University Hospital
HK inno.N Corporation

Completed

Safety and Efficacy of CJ-50300 in Healthy Volunteers

Smallpox

Korea, Republic of
Seoul National University Hospital
HK inno.N Corporation

Completed

Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers

Smallpox

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dryvax Dilution-Prev Vacc Adults

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Human Immune Responses Smallpox

Smallpox

United States
Seoul National University Hospital
HK inno.N Corporation

Completed

Safety and Immunogenicity of CJ-50300

Smallpox

Korea, Republic of
VaxGen

Unknown

Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers

Smallpox

United States
ClearNote Health

Recruiting

Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types

Diagnosis of Cancer of Various Organs

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)

Various Advanced Cancer

United States, Belgium, France, Germany, Japan, Korea, Republic of, Mexico, Netherlands, Spain, Taiwan, United Kingdom
Sanofi

Completed

Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults

Smallpox | Poxvirus Infection

France
National Institute of Allergy and Infectious Diseases...

Completed

Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox

Healthy

United States
ModernaTX, Inc.

Recruiting

A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

Smallpox | Mpox

United Kingdom
Bavarian Nordic

Completed

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

Smallpox

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274)

Various Advanced Cancer

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Romania, Russian Federation and more
Emergent BioSolutions

Completed

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

Smallpox

United States
Emergent BioSolutions

Completed

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Smallpox

United States
Bavarian Nordic
Biomedical Advanced Research and Development Authority

Completed

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

Smallpox

United States
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

Smallpox

Germany

Clinical Trials on Variola Major (Smallpox)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations